These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 12374519)

  • 1. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis.
    El-Serag HB; Graham DY; Richardson P; Inadomi JM
    Arch Intern Med; 2002 Oct; 162(18):2105-10. PubMed ID: 12374519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
    de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
    Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
    Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
    Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs.
    Graham DY
    Am J Med; 2001 Jan; 110(1A):58S-61S. PubMed ID: 11166000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of strategies for primary prevention of nonsteroidal anti-inflammatory drug-induced peptic ulcer disease.
    Ko CW; Deyo RA
    J Gen Intern Med; 2000 Jun; 15(6):400-10. PubMed ID: 10886475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Who needs prophylaxis of nonsteroidal anti-inflammatory drug-induced ulcers and what is optimal prophylaxis?
    Goldstein JL
    Eur J Gastroenterol Hepatol; 2000 Jun; 12 Suppl 1():S11-5. PubMed ID: 10929893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for changing the burden of nonsteroidal anti-inflammatory drug toxicity.
    Griffin MR; Scheiman JM
    Am J Med; 2001 Jan; 110(1A):33S-37S. PubMed ID: 11165994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.
    Vonkeman HE; Fernandes RW; van der Palen J; van Roon EN; van de Laar MA
    Arthritis Res Ther; 2007; 9(3):R52. PubMed ID: 17521422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
    Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
    Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
    Naesdal J; Wilson I
    Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Guidelines of prevention and treatment for NSAID-related peptic ulcers].
    Lee JH; Lee YC; Jeon SW; Kim JW; Lee SW; ;
    Korean J Gastroenterol; 2009 Nov; 54(5):309-17. PubMed ID: 19934612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
    Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of competing strategies for the prevention of recurrent peptic ulcer hemorrhage.
    Ofman J; Wallace J; Badamgarav E; Chiou CF; Henning J; Laine L
    Am J Gastroenterol; 2002 Aug; 97(8):1941-50. PubMed ID: 12190158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    ;
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
    Howden CW
    Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S5-11. PubMed ID: 10597118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
    Limmer S; Ittel TH; Wietholtz H
    Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.